Literature DB >> 15372065

The financial cost of optimising blood pressure control.

T Shiner1, L Simons, H Parkinson, A Khanbhai, V J Karthikeyan, V J Karthikeyen, G Nandhara, D G Beevers.   

Abstract

We have investigated the financial costs of attempts to optimise blood pressure control in patients referred to our blood pressure clinic. At first referral, the average blood pressure in the 262 patients studied were 167/97 mmHg and the monthly costs of the antihypertensive drugs was 23.44 pounds. After 1 year of clinic attendance, the blood pressure was reduced to 149/87 mmHg, and the average drug costs had risen to 30.68 pounds. For drug expenditure alone, the cost of reducing systolic blood pressure by 1 mmHg was 0.36p pounds (Euro 0.55, USD 0.55) and for diastolic blood pressure the cost-was 0.72p pounds (Euro 1.12, USD 1.13).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15372065     DOI: 10.1038/sj.jhh.1001778

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  3 in total

1.  Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial.

Authors:  Tazeen H Jafar; Muhammad Islam; Rasool Bux; Neil Poulter; Juanita Hatcher; Nish Chaturvedi; Shah Ebrahim; Peter Cosgrove
Journal:  Circulation       Date:  2011-09-19       Impact factor: 29.690

2.  Patient, clinician and logistic barriers to blood pressure control among adult hypertensives in rural district hospitals in Rwanda: a cross-sectional study.

Authors:  J P Sibomana; R L McNamara; T D Walker
Journal:  BMC Cardiovasc Disord       Date:  2019-10-21       Impact factor: 2.298

3.  [Evaluation of referral process of the hypertensive patient in Spain: DERIVA study].

Authors:  Nieves Martell-Claros; María Abad-Cardiel; Beatriz Álvarez-Álvarez; Jose Antonio García-Donaire; Alberto Galgo-Nafría
Journal:  Aten Primaria       Date:  2015-02-17       Impact factor: 1.137

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.